Oppenheimer Maintains Outperform on Mindray Medical Int'l

Oppenheimer is out with its report today on Mindray Medical Int'l (NYSE: MR), maintaining Outperform.

In its report, Oppenheimer writes, "We view MR as a dominant key player in China's medical device industry. We think MR will grow on the back of strong domestic market growth supported by government spending, continuing high demand from emerging markets and modest growth in developed countries. Its strong 1H11 results convince us that MR is growing above industry rates."

Oppenheimer maintains a $32 PT on MR.

Shares of MR closed Monday at $24.95, down 1.34% from Friday's close.